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Abstract 26 
While much research has been dedicated to understanding osteoporosis, the nature of mineral 27 
distribution and the mechanical property variation in diseased bone is poorly understood. The 28 
current study aimed to determine the effect of estrogen deficiency and bisphosphonate 29 
therapy on bone tissue properties using an ovine model of osteoporosis. Skeletally mature 30 
animals (4+ years) were divided into an ovariectomy group (ovx, n=20) and a non treatment 31 
control group (control, n=20). A zoledronic acid treated group was also included in which 32 
animals were estrogen deficient for 20 months prior to receiving treatment (Zol, n=4). Half of 33 
the control and ovx groups were euthanized 12 or 31 months post-operatively and all Zol 34 
animals were euthanised at 31 months. Individual trabeculae were removed from the 35 
proximal femur and at specific locations across the width of the trabeculae. The mineral 36 
content was measured using quantitative backscatter electron imaging and the modulus was 37 
measured using nanoindentation. 38 
The spatial distribution of tissue modulus and mineral content in bone from ovariectomised 39 
animals was similar to control. However, ovariectomy significantly reduced the overall 40 
mineral content and tissue modulus relative to the control group after 12 months. 41 
Interestingly, significant differences were not maintained 31 months post-OVX. Treatment 42 
with zoledronic acid increased the mineral content and tissue modulus relative to both the 43 
ovariectomised and control groups. Zoledronic acid was also found to alter the mineral and 44 
modulus gradients normally associated with healthy bone tissue. The current study provides 45 
evidence that both estrogen deficiency and zoledronic acid therapy significantly alter mineral 46 
content and the mechanical properties of trabecular tissue.  47 
 48 
 49 
 50 
Introduction 51 
Trabecular bone has a complex lamellar structure, and the degree of lamellar mineralisation 52 
increases with the distance from the trabecular surface to their centres (Renders et al., 2006). 53 
The distribution of mineral provides an inhomogeneous mechanical structure with the elastic 54 
modulus of trabecular bone increasing towards the centre of trabeculae (Brennan et al., 2009) 55 
along the same path as the degree of mineralisation (Mulder et al., 2007).  56 
 57 
Osteoporosis is a skeletal disease characterised by an imbalance between bone resorption and 58 
formation, which results in bone loss and deterioration of the trabecular microarchitecture 59 
and leads to an increased risk of fracture. Osteoporotic bone is believed to be less mineralised 60 
than healthy bone due to the increase in bone turnover seen following estrogen deficiency 61 
(Type I osteoporosis) and also the imbalance between resorption and formation that occurs 62 
with age (Type II osteoporosis). Consistent with this belief, mineral content is reduced in 63 
bone tissue from primate models of postmenopausal osteoporosis (Type I) and 64 
ovariectomised rats (Gadeleta et al., 2000; Cheng et al., 2009). However, others have found 65 
no change in mineral content (Li and Aspden 1997) or an increase in the mineral content 66 
following estrogen deficiency (Dickenson et al., 1981; Boyde et al., 1998; Ciarelli et al., 67 
2003; McNamara et al., 2006). Trabecular mineralisation also increases with age (Grynpas 68 
1993). While overall bone mass and bone mineral density is  reduced during estrogen 69 
deficiency, the yield strength and elastic modulus of the remaining tissue increased by 40–70 
90% relative to controls in an ovariectomzied rat model of osteoporosis (McNamara et al., 71 
2006). While variations in experimental methods, animal model or anatomical location might 72 
explain the discrepancies seen previously, it is still unclear how bone tissue mineral content 73 
and mechanical properties are altered during osteoporosis. Cellular processes and molecular 74 
signalling pathways governing pathological bone resorption have been identified to a certain 75 
extent; however, further research is required to comprehensively characterise the events that 76 
lead to bone fracture (McNamara 2010).  77 
A highly successful treatment for reducing the occurrence of osteoporotic fractures is the 78 
family of anti-resorptive drugs known as bisphosphonates which are potent inhibitors of 79 
osteoclast activity and thus bone resorption. Mineralisation is increased following treatment 80 
with bisphosphonates such as pamidronate (Grynpas et al., 1992), risedronate and alendronate 81 
(Burr et al., 2003; Day et al., 2004; Spadaro et al., 2006; Yao et al., 2006). In humans, the 82 
reduction of bone turnover by risedronate increased the mineral content in the iliac crest 83 
(Borah et al., 2005). The newest generation and most potent bisphosphonate, zoledronic acid, 84 
has also proven successful at preventing loss of bone structure and mechanical strength in 85 
vertebral and long bones of ovariectomised rats (Hornby et al., 2003) and preventing bone 86 
loss in postmenopausal women (Reid et al., 2002).  87 
 88 
In the current study we test the hypothesis that estrogen deficiency and zoledronic acid 89 
therapy alter bone tissue mineral content and microstructural modulus in an ovine 90 
ovariectomised model. Scanning Electron Microscopy with quantitative backscatter electron 91 
imaging (qBEI) and nanoindentation were carried out across the width of individual 92 
trabeculae from femoral bone of ovariectomized (OVX) sheep, OVX sheep treated with 93 
zoledronic acid and control animals to determine bone tissue mineral content and 94 
microstructural stiffness. Furthermore the results were compared with a previously published 95 
study from this group which examined the tissue modulus at an earlier time point (Brennan et 96 
al., 2009). 97 
 98 
 99 
Materials and Methods 100 
Forty four skeletally mature (aged 4-5 years) mixed breed ewes were randomly assigned into 101 
one of two groups, ovariectomy (OVX, n=24) or control (control, n=20) on which no 102 
operative procedure was carried out. All surgery was performed under an animal licence 103 
granted by the Irish Department of Health and subject to ethical approval. Animals were 104 
maintained at pasture and feeding and activity levels were the same for both groups. Twelve 105 
months post ovariectomy, half of each group was sacrificed at which point the animals were 106 
aged 5-6 years. Twenty months post-OVX, four OVX animals were randomly selected to 107 
serve as a bisphosphonate treated group, OVX plus zoledronic acid (Zol; Novartis Pharma, 108 
Basel, Switzerland). Each animal received a 5mg dose of zoledronic acid in 100mls of saline 109 
infused over 30 minutes via an indwelling jugular catheter. This procedure was repeated for a 110 
further four weeks, giving each animal a supra-pharmacological 25mg dose. All remaining 111 
animals were sacrificed 31 months post-OVX by which stage animals were 7-8 years of age. 112 
All bones were harvested and frozen at -20
o
C. Individual trabeculae were randomly selected 113 
and excised from the anteromedial region of the medullary cavity of the left proximal femur 114 
using a scalpel blade and forceps under 30X magnification as was described previously 115 
(Brennan et al., 2009).  116 
 117 
Quantitative Backscatter Electron Imaging (QBEI) 118 
Five trabeculae from each animal were assessed. Individual trabeculae were embedded in 119 
polymethylmethacrylate (PMMA) and planoparallel cuts were made to reveal a cross section 120 
of the trabeculae which was polished. Samples were mounted on individual scanning electron 121 
microscopy mounting stubs and were sputter-coated with carbon using a Bio Rad 122 
(Microscience Division) Carbon Coater, Model TB500. Quantitative backscatter electron 123 
imaging (QBEI) was carried out using a JEOL JSM-5410 LV Scanning Electron Microscope 124 
(SEM). A conventional backscattered electron detector (paired semiconductor type; JEOL), 125 
as supplied with the JEOL JSM-5410 LV microscope, was employed. An operating voltage 126 
of 15kV and a working distance of 10mm were employed during scanning. The grey-level 127 
was calibrated according to Roschger et al (Roschger et al., 1998). This method involves 128 
using two different reference materials, carbon (C) and aluminium (Al), and altering the 129 
brightness (offset voltage) and contrast (gain) conditions of the backscattered electron 130 
detector amplifier. Prior to testing of the bone samples, the brightness and contrast of the two 131 
standards were adjusted to give a grey-level index value of 25±1 and 225±1 for C and Al 132 
respectively.  Roschger determined that using the calibration technique the % weight calcium 133 
within a given sample could be evaluated using Equation 1 where x is the grey-level. 134 
Equation 1:    % Weight Calcium =−4.332 + 0.1733x 135 
Bone samples were mounted on stubs in the same sample holders as the standards and 136 
scanned by qBEI. Measurements of gray level were taken across the width of the trabeculae: 137 
in an outer ring (Superficial), half way towards the centre of the trabeculae (Intermediate) and 138 
in the centre of the trabeculae (Centre) (Figure 1).  139 
Scanning electron microscopy images of a typical trabecular cross section show the regions 140 
which were sampled (Figure 1). On the left is a low magnification image where the entire 141 
cross section of the individual trabeculae can be visualised. On the right hand side, a section 142 
of bone has been magnified and the individual lamellae are evident and can be clearly 143 
distinguished from neighbouring lamellae. At each point where a qBEI scan was performed a 144 
histogram of gray levels was obtained. The grey-level which corresponded to the maximum 145 
pixel count was analysed to calculate the % weight calcium, indicative of mineral content, 146 
according to the Roschger equation (Equation 1).  147 
Nanoindentation 148 
Five trabeculae from each animal were assessed. Individual trabeculae were mounted 149 
vertically in non-infiltrating dental stone (Suprastone, Kerr UK Ltd, England) and were cut 150 
using a diamond saw to create a cross section of the trabeculum. The surface was polished 151 
with a series of graded polishing cloths until finally a 0.25μm diamond suspension was used. 152 
A Nano Indenter XP (MTS Systems, Oakridge, TN) was used with a load and displacement 153 
resolution of 0.05μN and 0.01nm respectively. The indenter tip chosen was an AccuTip™ 154 
Berkovich diamond indenter tip, with defined elastic modulus of 1141GPa, a Poisson’s ratio 155 
equal to 0.07 and a radius of <50nm. A permanent hardness impression was made by driving 156 
the indenter tip into the sample for 90 seconds to a maximum load of 20mN, holding for 120 157 
seconds and unloading. This cycle was repeated 3 times at each location and the Young’s 158 
Modulus (E) was determined on the final unloading segment assuming a Poisson’s ratio for 159 
bone of 0.3. Indents were made across the individual trabeculae in the regions as described 160 
above in QBEI.  161 
 162 
Statistics 163 
To test for the magnitude of variance of intra- and inter-specimen differences (between sheep 164 
and between regions), a nested ANOVA was performed (Minitab
®
 Statistical Software). This 165 
analysis took into account the repeated measures made in each region and the multiple 166 
trabeculae analysed per sheep. A posthoc t-test was used to determine significant interactions. 167 
A p value of ≤ 0.05 was considered statistically significant. 168 
Results 169 
In the 12 month control group mineral content was significantly greater in the intermediate 170 
and centre regions than superficially (Figure 2). Comparison between the control and OVX 171 
groups showed a significant reduction in mineral content in the ovariectomy groups at all 172 
three locations. When the trabeculae were examined as a whole, a significant reduction in 173 
mineral content between the control (19.9±1.7%) and OVX groups (17.8±1.1%, p<0.001) 174 
was measured. 175 
 176 
At 31 months, mineral content in the control group was significantly increased in the 177 
intermediate and centre regions relative to the superficial region (Figure 2).  In the OVX 178 
group the mineral content was not significantly different between the superficial and either 179 
the intermediate or centre regions, albeit that a strong trend (p=0.09) was observed along the 180 
same pattern as at 12 months. In the zoledronic acid treated group, mineral content in the 181 
centre did not differ significantly from the intermediate and superficial regions.  182 
In contrast to the 12 month group, comparisons between the control and OVX groups at 31 183 
months found no significant difference in the level of mineralisation at any location. 184 
Treatment with zoledronic acid resulted in significantly increased mineralisation, in all three 185 
regions, relative to both the OVX and control groups (p<0.01). At 31 months no significant 186 
difference in the overall mineral content between the control (19.5±0.9%) and OVX groups 187 
(18.4±1.6%) was observed. As was the case with the individual locations, the overall 188 
mineralisation in the Zol group (21.4±1.8%) was significantly greater than both the control 189 
and OVX groups (p<0.005).  190 
 191 
The nanoindentation experiments showed results consistent with the qBEI study. The results 192 
from the 12 month group have been published previously (Brennan et al., 2009). Tissue 193 
modulus increased significantly in the intermediate and centre regions relative to the 194 
superficial region in trabeculae from both the control, and OVX groups. Comparison between 195 
the groups found that tissue modulus was significantly less in all three locations in the OVX 196 
group relative to the controls and overall the modulus was significantly less in the OVX 197 
group (17.3±1.3GPa, p<0.005) than the controls (20.7±2.4GPa). In the current study we 198 
found that at 31 months in the control group the tissue modulus was significantly less in the 199 
superficial region than the intermediate and centre locations (Figure 3). In the OVX group the 200 
modulus was also significantly less between the superficial region and the other two regions. 201 
In the zoledronic acid treated group no significant change in modulus was measured between 202 
the intermediate or centre regions relative to the superficial region. 31-months post-OVX the 203 
modulus did not differ significantly between the control and OVX groups at any location or 204 
overall (18.6±3.1GPa vs. 17.9±2.5GPa). However, treatment with zoledronic acid resulted in 205 
a significant increase in modulus at the centre and intermediate locations relative to both the 206 
control and OVX groups (p≤0.01). The overall modulus of the trabeculae treated with 207 
zoledronic acid (21.1±3.1GPa) was also significantly greater than the ovariectomised group 208 
but not the controls.   209 
 210 
Discussion 211 
  212 
The current study found that healthy bone tissue has mineral and modulus gradients that 213 
increase from the surface of trabeculae to the centre. A similar pattern was observed in the 214 
mineral and modulus profiles of trabeculae from ovariectomised animals. Estrogen deficiency 215 
reduced mineral content and tissue modulus across the width of the trabecula relative to the 216 
controls. Interestingly, after 31 months of estrogen deficiency the deterioration in material 217 
properties was not evident compared to 31 month controls. Zoledronic acid treatment 218 
significantly increased mineral content and tissue modulus relative to both OVX and control 219 
groups.  220 
Qualitative backscatter electron microscopy revealed that mineral content increased 221 
significantly towards the centre of healthy trabeculae at both time points. This result is not 222 
surprising as at any one time in normal bone about 20% of the trabecular surfaces are 223 
undergoing remodelling resulting in the formation of new, less mineralised bone along the 224 
surface (Eriksen et al., 1994; Ott 1996).  This results in a gradual increase in mineral towards 225 
the centre of the trabeculae. A similar pattern was observed with the nanoindentation results 226 
where bone modulus increased towards the centre of the trabeculae. These results correspond 227 
as expected, as bone mineralisation and modulus are positively correlated (Choi et al., 1990; 228 
Follet et al., 2004; Silva et al., 2004; Mulder et al., 2007). 229 
 230 
In the OVX group, QBEI showed a significant increase in mineral from the superficial region 231 
to the centre of trabeculae from animals 12 months post surgery. However, 31 months post-232 
OVX no statistical increase in mineral content towards the centre of trabeculae was observed. 233 
However, with the mineral content increasing from 17.7±1.7% in the superficial region to 234 
19.3±1.6% in the centre (p=0.09), there is a trend towards increased mineral content in the 235 
centre of the trabeculae from ovariectomised animals. These results suggest that estrogen 236 
deficiency does not alter the mineralisation gradient across the trabeculae as a significant 237 
difference in the level of mineral content from the edge of the trabeculae to the centre 238 
remains. The nanoindentation results support these results as significant increases in tissue 239 
modulus are also measured towards the centre of trabeculae at both time points. 240 
 241 
One of the most interesting results from this study was found by examining the intergroup 242 
variations over time. At 12 months a significant reduction in mineral content and modulus in 243 
the OVX group relative to the controls was measured. However, at 31 months there was no 244 
significant difference in mineral content or modulus between the OVX group and the controls 245 
suggesting that some change may take place between 12 and 31 months. Estrogens inhibit 246 
bone resorption by decreasing both osteoclast numbers and activity (Krassas and 247 
Papadopoulou 2001). Following ovariectomy a reduction in the levels of circulating 248 
hormones and an increase in bone resorption are expected. In a related study on the same 249 
animals, 12 month post-OVX a significant reduction in the level of circulating 17-β estradiol 250 
was measured in these animals immediately prior to sacrifice, which was accompanied by an 251 
increase in bone turnover and porosity and a reduction in bone strength (Kennedy et al., 252 
2009). These results corroborate the reduction in mineral content and tissue modulus seen 253 
after 12 months.  In another related study on the 31 month group animals, bone turnover 254 
continued to be elevated in the OVX group relative to the controls (Healy et al., 2010). 255 
However, the final bone turnover was lower in the 31 month OVX group than the 12 month 256 
OVX group while turnover in the controls was the same at 12 and 31 months. This result is 257 
consistent with the current study which did not find a significant reduction in mineral content 258 
after 31 months in the OVX group relative to the controls. It is also possible that fundamental 259 
changes to the secondary mineralisation process occur following long term estrogen 260 
deficiency, which may be a compensatory mechanism by the remaining tissue to return 261 
mineralisation to normal levels. This study has highlighted the importance of study duration 262 
when determining the effects of estrogen deficiency. These results may help to decipher the 263 
apparent discrepancies in mineral content following estrogen deficiency seen by other 264 
researchers.  265 
 266 
Zoledronic acid is a potent antiresorptive agent which prevents osteoclast activity. Under 267 
normal circumstances, bone remodelling occurs primarily on the trabecular surface. In this 268 
study neither mineral content nor tissue modulus increased significantly towards the centre of 269 
the trabeculae from animals which were treated with zoledronic acid. Thus, indications exist 270 
that trabecular bone is losing the significant mineral and modulus gradients that are 271 
associated with healthy trabecular bone. This result is consistent with a recent study which 272 
found that bisphosphonate treatment leads to homogeneous mineral distribution in cancellous 273 
bone and also that tissue homogenization may negatively impact bone quality (Gourion-274 
Arsiquaud et al., 2010). Furthermore, computational modeling has predicted that inhibition of 275 
resorption (for e.g. by antiresorptive agents) can lead to a less heterogenous mineral 276 
distribution (Ruffoni et al., 2008).    277 
 278 
In addition, this study showed that mineral content and tissue modulus were significantly 279 
increased following bisphosphonate treatment. Recently alendronate treatment has been 280 
shown to increase mineral content in ovariectomised rats (Bitto et al., 2008; Anumula et al., 281 
2010). Ibandronate and risedronate also increased the degree of mineralised bone and 282 
indentation modulus in ovariectomised rats (Shahnazari et al., 2010). Similarly zoledronic 283 
acid increased the bone mineralisation in ovariectomised rats (Cheng et al., 2009).  However, 284 
in the current study treatment with zoledronic acid not only restored mineral content and 285 
modulus to that of control but actually surpassed them. As bisphosphonates suppress bone 286 
remodelling, this allows more time for secondary mineralisation to proceed (Boivin and 287 
Meunier 2002). Previous work has suggested that the main mechanism of action of nitrogen 288 
containing bisphosphonates, of which zoledronic acid is one, is via inhibition of the 289 
mevalonate pathway in osteoclasts (Amin et al., 1992; Crick et al., 1997; Fisher et al., 2000) 290 
which ultimately prevents osteoclasts from attaching to the bone surface and thus resorbing 291 
bone.  However, evidence also suggests that bisphosphonates have a direct action on 292 
osteoblasts. In vitro studies on human osteoblasts found that zoledronic acid directly affected 293 
the proliferation and differentiation of these cells and thereby enhanced their bone forming 294 
potential (Reinholz et al., 2000; Pan et al., 2004). Although the exact mechanism by which 295 
bisphosphonates affect osteoblasts is unclear, zoledronic acid has also been shown to induce 296 
human osteoblast differentiation via inhibition of the mevalonate pathway (Reinholz et al., 297 
2002). In the current study zoledronic acid likely increased tissue mineral content and 298 
modulus above control levels either by reducing osteoclast activity to such a level as to allow 299 
increased secondary mineralisation to occur or by directly stimulating osteoblasts to produce 300 
more mineral. However, the reality is most probably a combination of both mechanisms.  301 
 302 
This study has a number of limitations, one of which is that due to ethical institution 303 
guidelines, a sham operated group was not used and rather a non-operated control was 304 
included. This was unlikely to have significantly impacted on this study, in particular limb 305 
loading, as those animals which underwent ovariectomy were only subject to anaesthesia for 306 
a short period of time (<30mins) and once the anaesthesia had worn off, the animals were 307 
immediately mobile. The total number of samples tested per group did differ due to the small 308 
sample size of the zoledronic acid treated group. While this is a limitation, the strong 309 
statistical significance seen would likely only be improved using larger sample sizes. A visual 310 
determination of the points for nanoindentation and also QBEI was made rather than 311 
employing a computational method. This allowed selection of the location which best 312 
represented the area of interest (i.e. superficial, intermediate or centre) whilst avoiding any 313 
holes or other artefacts (e.g. lacunae) in the bone. Whilst this does introduce an element of 314 
human error, different trabeculae were assessed in the nanoindentation study and the QBEI 315 
study, thus the two techniques are not being carried out on the same location. Another 316 
limitation of this study was the lack of any hormone analysis after 31 months. However, 317 
hormone analysis was carried out after 12 months and this showed conclusively significant 318 
reductions in the levels of circulating hormones (Kennedy et al., 2009).  319 
 320 
In conclusion this study has found that both mineral content and tissue modulus increase 321 
towards the centre of healthy trabecular bone and also in bone from ovariectomised animals. 322 
Ovariectomy was found to significantly reduce mineral content and tissue modulus below 323 
that of controls after 12 months. However, after 31 months no significant reductions were 324 
found in either mineral content or modulus. This indicates either a reduction in bone turnover 325 
between 12 and 31 months or a change in the secondary mineralisation process to return 326 
mineral levels to control values and this is worthy of further study. Treatment with zoledronic 327 
acid did significantly increase mineral content and tissue modulus relative to both the 328 
ovariectomised and control groups. Zoledronic acid treatment also results in a more 329 
homogeneous mineral content and modulus across the width of trabeculae. This may have 330 
implications for load distribution and fracture resistance at the trabecular level. In conclusion 331 
this study provides evidence that estrogen deficiency and zoledronic acid therapy 332 
significantly alter the content and distribution of mineral in trabecular tissue. 333 
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Figure 1: Scanning electron microscopy images of cross sections through individual 
trabeculae. On the left, the entire cross section can be visualised and the sampled regions are 
depicted. In the image on the right hand side, a higher magnification of the boxed area makes 
it possible to distinguish the various lamellae of the trabeculae.  
 
Figure 2: Bone mineral content across the width of trabeculae from control, ovariectomised 
and zoledronic acid treated animals at 12 and 31 months post–OVX (* greater than 
superficial region in that group; # less than control in that region p ≤ 0.05:  ^ greater than 
control and OVX in that region p≤0.01).  
 
Figure 3: Bone tissue modulus across the width of trabeculae from control, ovariectomised 
and zoledronic acid treated animals at 12 and 31 months post–OVX (* greater than 
superficial region in that group; # less than control in that region; ^ greater than control and 
OVX in that region p≤0.01).  
 
Figure Legends
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Conflict of Interest 
 
All authors have no conflicts of interest. 
Orlaith Brennan was involved in the conception and design of the ovine model and also the 
experimental design. She carried out the sample preparation, testing and the analysis and 
interpretation of data. She drafted the article and approved the final draft. 
 
Oran Kennedy was involved in the conception, design and implementation of the ovine 
model. He critically revised the manuscript and approved the final draft.  
 
Sue Rackard was involved in the conception and design of the ovine model. She also carried 
out all procedures on the animals. She critically revised the manuscript and approved the final 
draft. 
 
Clive Lee was involved in the conception and design of the ovine model and securing 
funding. He critically revised the manuscript and approved the final draft. 
 
Fergal O’Brien was involved in the conception and design of the ovine model and securing 
funding. He critically revised the manuscript and approved the final draft.  
 
Laoise McNamara was involved in the conception and design of the SEM study and securing 
funding. She critically revised the manuscript and approved the final draft.  
 
 
*Conflict of Interest Statement
